you're looking Alunbrig Generic Name: brigatinib Dosage Form: tablet, film coated Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Drug Images Support Group Q & A Pricing & Coupons Indications and Usage for Alunbrig Alunbrig is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Slideshow Clearing The Air: Signs, Symptoms and Treatment Options For Lung Cancer Alunbrig Dosage and Administration Recommended Dosing The recommended dosing regimen for Alunbrig is: 90 mg orally once daily for the first 7 days; if 90 mg is tolerated during the first 7 days, increase the dose to 180 mg orally once daily. Administer Alunbrig until disease progression or unacceptable toxicity. If Alunbrig is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose. Alunbrig may be taken with or without food. Instruct patients to swallow tablets whole. Do not crush or chew tablets. If a dose of Alunbrig is missed or vomiting occurs after taking a dose, do not administer an additional dose and take the next dose of Alunbrig at the scheduled time. Dose Modifications for Adverse Reactions Alunbrig dose modification levels are summarized in Table 1. Table 1: Recommended Alunbrig Dose Reduction Levels Dose Dose Reduction Levels First Second Third * Not applicable 90 mg once daily 60 mg once daily permanently discontinue N/A * 180 mg once daily 120 mg once daily 90 mg once daily 60 mg once daily Once reduced for adverse reactions, do not subsequently increase the dose of Alunbrig. Permanently discontinue Alunbrig if patients are unable to tolerate the 60 mg once daily dose. Recommendations for dose modifications of Alunbrig for the management of adverse reactions are provided in Table 2. Table 2: Recommended Alunbrig Dose Modifications for Adverse Reactions Adverse Reaction Severity * Dose Modification bpm = beats per minute; DBP = diastolic blood pressure; HR = heart rate; SBP = systolic blood pressure; ULN = upper limit of normal * Graded per National Cancer Institute Common Terminology Criteria for Adverse Events. Version 4.0 (NCI CTCAE v4). Interstitial Lung Disease (ILD) /Pneumonitis [see Warnings and Precautions (5.1) ] Grade 1 If new pulmonary symptoms occur during the first 7 days of treatment, withhold Alunbrig until recovery to baseline, then resume at same dose and do not escalate to 180 mg if ILD/pneumonitis is suspected. If new pulmonary symptoms occur after the first 7 days of treatment, withhold Alunbrig until recovery to baseline, then resume at same dose. If ILD/pneumonitis recurs, permanently discontinue Alunbrig. Grade 2 If new pulmonary symptoms occur during the first 7 days of treatment, withhold Alunbrig until recovery to baseline. Resume at next lower dose (Table 1) and do not dose escalate if ILD/pneumonitis is suspected. If new pulmonary symptoms occur after the first 7 days of treatment, withhold Alunbrig until recovery to baseline. If ILD/pneumonitis is suspected, resume at next lower dose (Table 1); otherwise, resume at same dose. If ILD/pneumonitis recurs, permanently discontinue Alunbrig. Grade 3 or 4 Permanently discontinue Alunbrig for ILD/pneumonitis. Hypertension [see Warnings and Precautions (5.2) ] Grade 3 hypertension (SBP greater than or equal to 160 mmHg or DBP greater than or equal to 100 mmHg, medical intervention indicated, more than one anti-hypertensive drug, or more intensive therapy than previously used indicated) Withhold Alunbrig until hypertension has recovered to Grade 1 or less (SBP less than 140 mmHg and DBP less than 90 mmHg), then resume Alunbrig at next lower dose (Table 1). Recurrence: withhold Alunbrig until recovery to Grade 1 or less, and resume at next lower dose (Table 1) or permanently discontinue treatment. Grade 4 hypertension (life-threatening consequences, urgent intervention indicated) Withhold Alunbrig until recovery to Grade 1 or less, and resume at next lower dose (Table 1) or permanently discontinue treatment. Recurrence: permanently discontinue Alunbrig for recurrence of Grade 4 hypertension. Bradycardia (HR less than 60 bpm) [see Warnings and Precautions (5.3) ] Symptomatic bradycardia Withhold Alunbrig until recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above. If a concomitant medication known to cause bradycardia is identified and discontinued or dose-adjusted, resume Alunbrig at same dose upon recovery to asymptomatic bradycardia or to resting heart rate of 60 bpm or above. If no concomitant medication known to cause bradycardia is identified, or if contributing concomitant medications are not discontinued or dose-adjusted, resume Alunbrig at next lower dose (Table 1) upon recovery to asymptomatic bradycardia or to resting heart rate of 60 bpm or above. Bradycardia with life-threatening consequences, urgent intervention indicated Permanently discontinue Alunbrig if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued or dose-adjusted, resume Alunbrig at next lower dose (Table 1) upon recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above, with frequent monitoring as clinically indicated. Recurrence: permanently discontinue Alunbrig. Visual Disturbance [see Warnings and Precautions (5.4) ] Grade 2 or 3 visual disturbance Withhold Alunbrig until recovery to Grade 1 or baseline, then resume at the next lower dose (Table 1). Grade 4 visual disturbance Permanently discontinue Alunbrig. Creatine Phosphokinase (CPK) Elevation [see Warnings and Precautions (5.5) ] Grade 3 CPK elevation (greater than 5.0 ULN) Withhold Alunbrig until recovery to Grade 1 or less (less than or equal to 2.5 ULN) or to baseline, then resume Alunbrig at same dose. Grade 4 CPK elevation (greater than 10.0 ULN) or recurrence of Grade 3 elevation Withhold Alunbrig until recovery to Grade 1 or less (less than or equal to 2.5 ULN) or to baseline, then resume Alunbrig at next lower dose (Table 1). Lipase/Amylase Elevation [see Warnings and Precautions (5.6) ] Grade 3 lipase or amylase elevation (greater than 2.0 ULN) Withhold Alunbrig until recovery to Grade 1 or less (less than or equal to 1.5 ULN) or to baseline, then resume Alunbrig at same dose. Grade 4 lipase or amylase elevation (greater than 5.0 ULN) or recurrence of Grade 3 elevation Withhold Alunbrig until recovery to Grade 1 or less (less than or equal to 1.5 ULN) or to baseline, then resume Alunbrig at next lower dose (Table 1). Hyperglycemia [see Warnings and Precautions (5.7) ] Grade 3 (greater than 250 mg/dL or 13.9 mmol/L) or greater If adequate hyperglycemic control cannot be achieved with optimal medical management, withhold Alunbrig until adequate hyperglycemic control is achieved and consider reduction to the next dose (Table 1) or permanently discontinue Alunbrig. Other Grade 3 Withhold Alunbrig until recovery to baseline, then resume at same dose. Recurrence: withhold Alunbrig until recovery to baseline, then resume at next lower dose or discontinue Alunbrig (Table 1). Grade 4 First occurrence: either withhold Alunbrig until recovery to baseline and resume at next lower dose (Table 1) or permanently discontinue. Permanently discontinue Alunbrig for recurrence. Dose Modification for Strong CYP3A Inhibitors Avoid concomitant use of strong CYP3A inhibitors during treatment with Alunbrig [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . If concomitant use of a strong CYP3A inhibitor cannot be avoided, reduce the Alunbrig once daily dose by approximately 50% (i.e., from 180 mg to 90 mg, or from 90 mg to 60 mg). After discontinuation of a strong CYP3A inhibitor, resume the Alunbrig dose that was tolerated prior to initiating the strong CYP3A inhibitor. Dosage Forms and Strengths 180 mg, oval, white to off-white film-coated tablet with "U13" debossed on one side and plain on the other side 90 mg, oval, white to off-white film-coated tablet with "U7" debossed on one side and plain on the other side 30 mg, round, white to off-white film-coated tablet with "U3" debossed on one side and plain on the other side Contraindications None. Warnings and Precautions Interstitial Lung Disease (ILD)/Pneumonitis Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with Alunbrig. In Trial ALTA (ALTA), ILD/pneumonitis occurred in 3.7% of patients in the 90 mg group (90 mg once daily) and 9.1% of patients in the 90 180 mg group (180 mg once daily with 7-day lead-in at 90 mg once daily). Adverse reactions consistent with possible ILD/pneumonitis occurred early (within 9 days of initiation of Alunbrig; median onset was 2 days) in 6.4% of patients, with Grade 3 to 4 reactions occurring in 2.7%. Monitor for new or worsening respiratory symptoms (e.g., dyspnea, cough, etc.), particularly during the first week of initiating Alunbrig. Withhold Alunbrig in any patient with new or worsening respiratory symptoms, and promptly evaluate for ILD/pneumonitis or other causes of respiratory symptoms (e.g., pulmonary embolism, tumor progression, and infectious pneumonia). For Grade 1 or 2 ILD/pneumonitis, either resume Alunbrig with dose reduction according to Table 1 after recovery to baseline or permanently discontinue Alunbrig. Permanently discontinue Alunbrig for Grade 3 or 4 ILD/pneumonitis or recurrence of Grade 1 or 2 ILD/pneumonitis [see Dosage and Administration (2.2) and Adverse Reactions (6.1) ] . Hypertension In ALTA, hypertension was reported in 11% of patients in the 90 mg group who received Alunbrig and 21% of patients in the 90 180 mg group. Grade 3 hypertension occurred in 5.9% of patients overall. Control blood pressure prior to treatment with Alunbrig. Monitor blood pressure after 2 weeks and at least monthly thereafter during treatment with Alunbrig. Withhold Alunbrig for Grade 3 hypertension despite optimal antihypertensive therapy. Upon resolution or improvement to Grade 1 severity, resume Alunbrig at a reduced dose. Consider permanent discontinuation of treatment with Alunbrig for Grade 4 hypertension or recurrence of Grade 3 hypertension [see Dosage and Administration (2.2) and Adverse Reactions (6.1) ]. Use caution when administering Alunbrig in combination with antihypertensive agents that cause bradycardia [see Warnings and Precautions (5.3) ] . Bradycardia Bradycardia can occur with Alunbrig. In ALTA, heart rates less than 50 beats per minute (bpm) occurred in 5.7% of patients in the 90 mg group and 7.6% of patients in the 90 180 mg group. Grade 2 bradycardia occurred in 1 (0.9%) patient in the 90 mg group. Monitor heart rate and blood pressure during treatment with Alunbrig. Monitor patients more frequently if concomitant use of drug known to cause bradycardia cannot be avoided [see Warnings and Precautions (5.2) ] . For symptomatic bradycardia, withhold Alunbrig and review concomitant medications for those known to cause bradycardia. If a concomitant medication known to cause bradycardia is identified and discontinued or dose adjusted, resume Alunbrig at the same dose following resolution of symptomatic bradycardia; otherwise, reduce the dose of Alunbrig following resolution of symptomatic bradycardia. Discontinue Alunbrig for life-threatening bradycardia if no contributing concomitant medication is identified [see Dosage and Administration (2.2) ]. Visual Disturbance In ALTA, adverse reactions leading to visual disturbance including blurred vision, diplopia, and reduced visual acuity, were reported in 7.3% of patients receiving Alunbrig in the 90 mg group and 10% of patients in the 90 180 mg group. Grade 3 macular edema and cataract occurred in one patient each in the 90 180 mg group. Advise patients to report any visual symptoms. Withhold Alunbrig and obtain an ophthalmologic evaluation in patients with new or worsening visual symptoms of Grade 2 or greater severity. Upon recovery of Grade 2 or Grade 3 visual disturbances to Grade 1 severity or baseline, resume Alunbrig at a reduced dose. Permanently discontinue treatment with Alunbrig for Grade 4 visual disturbances [see Dosage and Administration (2.2) and Adverse Reactions (6.1) ]. Creatine Phosphokinase (CPK) Elevation In ALTA, creatine phosphokinase (CPK) elevation occurred in 27% of patients receiving Alunbrig in the 90 mg group and 48% of patients in the 90 mg 180 mg group. The incidence of Grade 3-4 CPK elevation was 2.8% in the 90 mg group and 12% in the 90 180 mg group. Dose reduction for CPK elevation occurred in 1.8% of patients in the 90 mg group and 4.5% in the 90 180 mg group. Advise patients to report any unexplained muscle pain, tenderness, or weakness. Monitor CPK levels during Alunbrig treatment. Withhold Alunbrig for Grade 3 or 4 CPK elevation. Upon resolution or recovery to Grade 1 or baseline, resume Alunbrig at the same dose or at a reduced dose as described in Table 2 [see Dosage and Administration (2.2) and Adverse Reactions (6.1) ] . Pancreatic Enzyme Elevation In ALTA, amylase elevation occurred in 27% of patients in the 90 mg group and 39% of patients in the 90 180 mg group. Lipase elevations occurred in 21% of patients in the 90 mg group and 45% of patients in the 90 180 mg group. Grade 3 or 4 amylase elevation occurred in 3.7% of patients in the 90 mg group and 2.7% of patients in the 90 180 mg group. Grade 3 or 4 lipase elevation occurred in 4.6% of patients in the 90 mg group and 5.5% of patients in the 90 180 mg group. Monitor lipase and amylase during treatment with Alunbrig. Withhold Alunbrig for Grade 3 or 4 pancreatic enzyme elevation. Upon resolution or recovery to Grade 1 or baseline, resume Alunbrig at the same dose or at a reduced dose as described in Table 2 [see Dosage and Administration (2.2) and Adverse Reactions (6.1) ]. Hyperglycemia In ALTA, 43% of patients who received Alunbrig experienced new or worsening hyperglycemia. Grade 3 hyperglycemia, based on laboratory assessment of serum fasting glucose levels, occurred in 3.7% of patients. Two of 20 (10%) patients with diabetes or glucose intolerance at baseline required initiation of insulin while receiving Alunbrig. Assess fasting serum glucose prior to initiation of Alunbrig and monitor periodically thereafter. Initiate or optimize anti-hyperglycemic medications as needed. If adequate hyperglycemic control cannot be achieved with optimal medical management, withhold Alunbrig until adequate hyperglycemic control is achieved and consider reducing the dose of Alunbrig as described in Table 1 or permanently discontinuing Alunbrig [see Dosage and Administration (2.2) and Adverse Reactions (6.1) ] . Embryo-Fetal Toxicity Based on its mechanism of action and findings in animals, Alunbrig can cause fetal harm when administered to pregnant women. There are no clinical data on the use of Alunbrig in pregnant women. Administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by AUC at 180 mg once daily) as well as increased post implantation loss, malformations, and decreased fetal body weight at doses of 25 mg/kg/day (approximately 1.26 times the human exposure at 180 mg once daily) or higher. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with Alunbrig and for at least 4 months following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose of Alunbrig [see Use in Specific Populations (8.1 and 8.3) and Clinical Pharmacology (12.1) ]. Adverse Reactions The following adverse reactions are discussed in greater detail in other sections of the prescribing information: Interstitial Lung Disease (ILD)/Pneumonitis [see Warnings and Precautions (5.1) ] Hypertension [see Warnings and Precautions (5.2) ] Bradycardia [see Warnings and Precautions (5.3) ] Visual Disturbance [see Warnings and Precautions (5.4) ] Creatine Phosphokinase (CPK) Elevation [see Warnings and Precautions (5.5) ] Pancreatic Enzyme Elevation [see Warnings and Precautions (5.6) ] Hyperglycemia [see Warnings and Precautions (5.7) ] Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of Alunbrig was evaluated in 219 patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who received at least one dose of Alunbrig in ALTA after experiencing disease progression on crizotinib. Patients received Alunbrig 90 mg once daily continuously (90 mg group) or 90 mg once daily for 7 days followed by 180 mg once daily (90 180 mg group). The median duration of treatment was 7.5 months in the 90 mg group and 7.8 months in the 90 180 mg group. A total of 150 (68%) patients were exposed to Alunbrig for greater than or equal to 6 months and 42 (19%) patients were exposed for greater than or equal to one year. The study population characteristics were: median age 54 years (range: 18 to 82), age less than 65 years (77%), female (57%), White (67%), Asian (31%), Stage IV disease (98%), NSCLC adenocarcinoma histology (97%), never or former smoker (95%), ECOG Performance Status (PS) 0 or 1 (93%), and brain metastases at baseline (69%) [see Clinical Studies (14) ] . Serious adverse reactions occurred in 38% of patients in the 90 mg group and 40% of patients in the 90 180 mg group. The most common serious adverse reactions were pneumonia (5.5% overall, 3.7% in the 90 mg group, and 7.3% in the 90 180 mg group) and ILD/pneumonitis (4.6% overall, 1.8% in the 90 mg group and 7.3% in the 90 180 mg group). Fatal adverse reactions occurred in 3.7% of patients and consisted of pneumonia (2 patients), sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis and urosepsis (1 patient each). In ALTA, 2.8% of patients in the 90 mg group and 8.2% of patients in the 90 180 mg group permanently discontinued Alunbrig for adverse reactions. The most frequent adverse reactions that led to discontinuation were ILD/pneumonitis (0.9% in the 90 mg group and 1.8% in the 90 180 mg group) and pneumonia (1.8% in the 90 180 mg group only). In ALTA, 14% of patients required a dose reduction due to adverse reactions (7.3% in the 90 mg group and 20% in the 90 180 mg group). The most common adverse reaction that led to dose reduction was increased creatine phosphokinase for both regimens (1.8% in the 90 mg group and 4.5% in the 90 180 mg group). Table 3 and Table 4 summarize the common adverse reactions and laboratory abnormalities observed in ALTA. Table 3: Adverse Reactions in 10% (All Grades * ) or 2% (Grades 3-4) of Patients by Dose Group in ALTA (N=219) Adverse Reactions 90 mg once daily N = 109 90 180 mg once daily N = 110 All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) * Per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Includes abdominal distension, abdominal pain, and epigastric discomfort Includes asthenia and fatigue Includes dyspnea and exertional dyspnea Includes one Grade 5 event # Includes headache and sinus headache Þ Includes peripheral sensory neuropathy and paresthesia ß Includes acneiform dermatitis, exfoliative rash, rash, pruritic rash, and pustular rash à Includes musculoskeletal pain and myalgia è Includes diplopia, photophobia, blurred vision, reduced visual acuity, visual impairment, vitreous floaters, visual field defect, macular edema, and vitreous detachment Gastrointestinal Disorders Nausea 33 0.9 40 0.9 Diarrhea 19 0 38 0 Vomiting 24 1.8 23 0 Constipation 19 0.9 15 0 Abdominal Pain 17 0 10 0 General Disorders And Administration Site Conditions Fatigue 29 1.8 36 0 Pyrexia 14 0 6.4 0.9 Respiratory, Thoracic And Mediastinal Disorders Cough 18 0 34 0 Dyspnea 27 2.8 21 1.8 ILD/Pneumonitis 3.7 1.8 9.1 2.7 Hypoxia 0.9 0 2.7 2.7 Nervous System Disorders Headache # 28 0 27 0.9 Peripheral Neuropathy Þ 13 0.9 13 1.8 Skin And Subcutaneous Tissue Disorders Rash ß 15 1.8 24 3.6 Vascular Disorders Hypertension 11 5.5 21 6.4 Musculoskeletal And Connective Tissue Disorders Muscle Spasms 12 0 17 0 Back pain 10 1.8 15 1.8 Myalgia à 9.2 0 15 0.9 Arthralgia 14 0.9 14 0 Pain in extremity 11 0 3.6 0.9 Metabolism And Nutrition Disorders Decreased Appetite 22 0.9 15 0.9 Eye Disorders Visual Disturbance è 7.3 0 10 0.9 Infections Pneumonia 4.6 2.8 10 5.5 Psychiatric Disorders Insomnia 11 0 7.3 0 Table 4: Laboratory Abnormalities in 20% (All Grades * ) of Patients by Regimen in ALTA (N=219) Laboratory Abnormality 90 mg once daily N= 109 90 180 mg once daily N=110 All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) * Per CTCAE version 4.0 Elevated blood insulin was also observed in both regimens Chemistry Increased aspartate aminotransferase 38 0.9 65 0 Hyperglycemia 38 3.7 49 3.6 Increased creatine phosphokinase 27 2.8 48 12 Increased lipase 21 4.6 45 5.5 Increased alanine aminotransferase 34 0 40 2.7 Increased amylase 27 3.7 39 2.7 Increased alkaline phosphatase 15 0.9 29 0.9 Decreased phosphorous 15 1.8 23 3.6 Prolonged activated partial thromboplastin time 22 1.8 20 0.9 Hematology Anemia 23 0.9 40 0.9 Lymphopenia 19 2.8 27 4.5 Drug Interactions Drugs That May Increase Brigatinib Plasma Concentrations Strong CYP3A Inhibitors Coadministration of itraconazole, a strong CYP3A inhibitor, increased brigatinib plasma concentrations and may result in increased adverse reactions [see Clinical Pharmacology (12.3) ] . Avoid the concomitant use of strong CYP3A inhibitors with Alunbrig, including but not limited to certain antivirals (e.g., boceprevir, cobicistat, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir), macrolide antibiotics (e.g., clarithromycin), antifungals (e.g., itraconazole, ketoconazole, posaconazole, voriconazole), and conivaptan. Avoid grapefruit or grapefruit juice as it may also increase plasma concentrations of brigatinib [see Clinical Pharmacology (12.3) ] . If concomitant use of a strong CYP3A inhibitor cannot be avoided, reduce the dose of Alunbrig by approximately 50% [see Dosage and Administration (2.3) ] . Drugs That May Decrease Brigatinib Plasma Concentrations Strong CYP3A Inducers Coadministration of Alunbrig with rifampin, a strong CYP3A inducer, decreased brigatinib plasma concentrations and may result in decreased efficacy [see Clinical Pharmacology (12.3) ] . Avoid the concomitant use of strong CYP3A inducers with Alunbrig, including but not limited to rifampin, carbamazepine, phenytoin, and St. John's Wort [see Clinical Pharmacology (12.3) ] . Drugs That May Have Their Plasma Concentrations Altered by Brigatinib CYP3A Substrates Brigatinib induces CYP3A in vitro and may decrease concentrations of CYP3A substrates. Coadministration of Alunbrig with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and loss of efficacy of CYP3A substrates [see Use in Specific Populations (8.3) ] . USE IN SPECIFIC POPULATIONS Pregnancy Risk Summary Based on its mechanism of action and findings in animals, Alunbrig can cause fetal harm when administered to a pregnant woman [see Data and Clinical Pharmacology (12.1) ] . There are no clinical data on the use of Alunbrig in pregnant women. Administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by AUC at 180 mg once daily) as well as increased post-implantation loss, malformations, and decreased fetal body weight at doses of 25 mg/kg/day (approximately 1.26 times the human exposure at 180 mg once daily) or greater. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryo-fetal development study in which pregnant rats were administered daily doses of brigatinib during organogenesis, dose-related skeletal (incomplete ossification, small incisors) and visceral anomalies were observed at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by AUC at 180 mg once daily). Malformations observed at 25 mg/kg/day (approximately 1.26 times the human AUC at 180 mg once daily) included anasarca (generalized subcutaneous edema), anophthalmia (absent eyes), forelimb hyperflexion, small, short and/or bent limbs, multiple fused ribs, bent scapulae, omphalocele (intestine protruding into umbilicus), and gastroschisis (intestines protruding through a defect in the abdominal wall) along with visceral findings of moderate bilateral dilatation of the lateral ventricles. Lactation Risk Summary There are no data regarding the secretion of brigatinib in human milk or its effects on the breastfed infant or milk production. Because of the potential for adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment with Alunbrig and for 1 week following the final dose. Females and Males of Reproductive Potential Contraception Alunbrig can cause fetal harm [see Use in Specific Populations (8.1) ]. Females Advise females of reproductive potential to use effective non-hormonal contraception during treatment with Alunbrig and for at least 4 months after the final dose. Counsel patients to use a non-hormonal method of contraception since Alunbrig can render some hormonal contraceptives ineffective [ see Drug Interaction (7.3] ) . Males Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with Alunbrig and for at least 3 months after the final dose [see Nonclinical Toxicology (13.1) ] . Infertility Based on findings in male reproductive organs in animals, Alunbrig may cause reduced fertility in males [see Nonclinical Toxicology (13.1) ] . Pediatric Use The safety and efficacy of Alunbrig in pediatric patients have not been established. Geriatric Use Clinical studies of Alunbrig did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. Of the 222 patients in ALTA, 19.4% were 65-74 years and 4.1% were 75 years or older. No clinically relevant differences in safety or efficacy were observed between patients 65 years and younger patients. Hepatic Impairment No dose adjustment is recommended for patients with mild hepatic impairment (total bilirubin within upper limit of normal [ULN] and AST greater than ULN or total bilirubin greater than 1 and up to 1.5 times ULN and any AST). The pharmacokinetics and safety of Alunbrig in patients with moderate or severe hepatic impairment have not been studied [see Clinical Pharmacology (12.3) ] . Renal Impairment No dose adjustment is recommended for patients with mild and moderate renal impairment [creatinine clearance (CL cr ) 30 to 89 mL/min estimated by Cockcroft-Gault)]. The pharmacokinetics and safety of Alunbrig in patients with severe renal impairment (CL cr 15 to 29 mL/min estimated by Cockcroft-Gault) have not been studied [see Clinical Pharmacology (12.3) ] . Alunbrig Description Brigatinib is a kinase inhibitor. The chemical name for brigatinib is 5-chloro-N 4 -[2-(dimethylphosphoryl)phenyl]-N 2 -2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine. The molecular formula is C 29 H 39 ClN 7 O 2 P which corresponds to a formula weight of 584.10 g/mol. Brigatinib has no chiral centers. The chemical structure is shown below: Brigatinib is an off-white to beige/tan solid. The pK a s were determined to be: 1.73 0.02 (base), 3.65 0.01 (base), 4.72 0.01 (base), and 8.04 0.01 (base). Alunbrig is supplied for oral use as film-coated tablets containing 180 mg, 90 mg or 30 mg of brigatinib and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide. Alunbrig - Clinical Pharmacology Mechanism of Action Brigatinib is a tyrosine kinase inhibitor with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations. Brigatinib inhibited autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signaling proteins STAT3, AKT, ERK1/2, and S6 in in vitro and in vivo assays. Brigatinib also inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice. At clinically achievable concentrations ( 500 nM), brigatinib inhibited the in vitro viability of cells expressing EML4-ALK and 17 mutant forms associated with resistance to ALK inhibitors including crizotinib, as well as EGFR-Del (E746-A750), ROS1-L2026M, FLT3-F691L, and FLT3-D835Y. Brigatinib exhibited in vivo anti-tumor activity against 4 mutant forms of EML4-ALK, including G1202R and L1196M mutants identified in NSCLC tumors in patients who have progressed on crizotinib. Brigatinib also reduced tumor burden and prolonged survival in mice implanted intracranially with an ALK-driven tumor cell line. Pharmacodynamics Brigatinib exposure-response relationships and the time course of the pharmacodynamic response are unknown. Cardiac Electrophysiology The QT interval prolongation potential of Alunbrig was assessed in 123 patients following once daily Alunbrig doses of 30 mg (1/6 th of the approved 180 mg dose) to 240 mg (1.3 times the approved 180 mg dose). Alunbrig did not prolong the QT interval to a clinically relevant extent. Pharmacokinetics The geometric mean (CV%) steady-state maximum concentration (C max ) of brigatinib at Alunbrig doses of 90 mg and 180 mg once daily was 552 (65%) ng/mL and 1452 (60%) ng/mL, respectively, and the corresponding area under the concentration-time curve (AUC 0-Tau ) was 8165 (57%) ng h/mL and 20276 (56%) ng h/mL. After a single dose and repeat dosing of Alunbrig, systemic exposure of brigatinib was dose proportional over the dose range of 60 mg (0.3 times the approved 180 mg dose) to 240 mg (1.3 times the approved 180 mg dose) once daily. The mean accumulation ratio after repeat dosing was 1.9 to 2.4. Absorption Following administration of single oral doses of Alunbrig of 30 to 240 mg, the median time to peak concentration (T max ) ranged from 1 to 4 hours. Effect of Food Brigatinib C max was reduced by 13% with no effect on AUC in healthy subjects administered Alunbrig after a high fat meal (approximately 920 calories, 58 grams carbohydrate, 59 grams fat and 40 grams protein) compared to the C max and AUC after overnight fasting. Distribution Brigatinib is 66% bound to human plasma proteins and the binding is not concentration-dependent in vitro. The blood-to-plasma concentration ratio is 0.69. Following oral administration of Alunbrig 180 mg once daily, the mean apparent volume of distribution (V z/ F) of brigatinib at steady-state was 153 L. Elimination Following oral administration of Alunbrig 180 mg once daily, the mean apparent oral clearance (CL/F) of brigatinib at steady-state is 12.7 L/h and the mean plasma elimination half-life is 25 hours. Metabolism Brigatinib is primarily metabolized by CYP2C8 and CYP3A4 in vitro. Following oral administration of a single 180 mg dose of radiolabeled brigatinib to healthy subjects, N-demethylation and cysteine conjugat the reality
most department stores Alunbrig today
EmoticonEmoticon